Longboard stock soars on heels of positive topline data for seizure medication

Long­board Phar­ma­ceu­ti­cals’ stock $LBPH sky­rock­et­ed by more than 200% Tues­day af­ter the com­pa­ny re­leased topline da­ta from its study for an oral drug to treat seizures as­so­ci­at­ed with de­vel­op­men­tal and epilep­tic en­cephalopathies.

Long­board pub­lished ini­tial re­sults from Phase Ib/IIa of the com­pa­ny’s PA­CIF­IC study, which is eval­u­at­ing bex­i­cas­erin, a 5-HT2C re­cep­tor su­per­ag­o­nist. The study looked at 52 peo­ple aged 12 to 65 with DEE in the US and Aus­tralia and demon­strat­ed a 53% seizure re­duc­tion com­pared to about 21% in the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.